Your Health, We Care
Release date: 2024-08-08 17:15:10 Recommended: 138
Capmatinib targets the activity of MET receptors and blocks the tumor cell growth signaling pathway driven by MET receptors, enabling effective treatment for patients with non-small cell lung cancer with specific gene mutations. With the gradual promotion and application around the world, capmatinib will bring hope and good news to more patients.
At present, capmatinib has been marketed in China, but it has not yet been included in the medical insurance reimbursement, and patients need to buy it at their own expense. Before purchasing and using drugs, it is necessary to understand the therapeutic effect of the drugs, which should be organized according to the drug instructions as follows:
Sixty-eight percent of treatment-naïve patients responded, 5 percent had a complete response, and 63 percent had a partial response. Forty-four percent of patients with prior therapy responded, all with partial responses.
The median duration of treatment-naïve patients was 16.6 months, and 49% of patients had a ≥ 12 months of response. The median duration of prior therapy was 9.7 months, and 36% of patients had a ≥ 12 months.
Capmatinib has shown lasting efficacy in the treatment of METex14-mutated NSCLC patients, so which special populations need to be paid more attention to when taking the drug?
Animal studies have shown that capmatinib may cause harm to the fetus. There are currently no data on human pregnancies, and it is advisable to inform pregnant women about the potential risks.
There are no data on the presence of capmatinib or metabolites in breast milk or effects on nursing infants. Serious adverse effects may occur in infants, and it is recommended not to breastfeed during treatment and for at least a week after the last dose.
Animal data suggest that capmatinib may cause fetal malformations. The pregnancy status of the female patient should be confirmed before treatment. It is recommended that women and men of childbearing potential use effective contraception during treatment and for at least a week after the last dose.
[Warm tips] Before starting treatment, patients should learn more about the use of drugs and follow the doctor's medication instructions.
